The effect of pioglitazone treatment on 15-epi-lipoxin A 4 levels in patients with type 2 diabetes

Atherosclerosis

Volumn 223, Issue 1, 2012, Pages 204-208

  Gutierrez, Absalon D ^a   Sathyanarayana, Padma ^a   Konduru, Somasekhar ^a   Ye, Yumei ^b   Birnbaum, Yochai ^a   Bajaj, Mandeep ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

15 Epi lipoxin A 4; Adiponectin; Inflammation; Insulin resistance; Pioglitazone

Indexed keywords

15 EPI LIPOXIN A4; ADIPONECTIN; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; LIPOXIN A; PIOGLITAZONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT DURATION;

ADIPONECTIN; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FATTY ACIDS, NONESTERIFIED; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPOXINS; MALE; MIDDLE AGED; TEXAS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84863097684     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.04.016     Document Type: Article

References (37)

1. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 1979, 241:2035-2038.
2. Malmberg K., Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988, 9:259-264.
3. Kalaitzidis R.G., Sarafidis P.A., Bakris G.L. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des 2009, 15:529-536.
4. 4 in the rat heart. Prostaglandins Other Lipid Mediat 2007, 83:89-98.
5. 4 by pioglitazone and atorvastatin in the rat. Circulation 2006, 114:929-935.
6. Ye Y., Lin Y., Perez-Polo J.R., Uretsky B.F., Ye Z., Tieu B.C., et al. Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production. J Immunol 2008, 181:3515-3523.
7. Ariel A., Chiang N., Arita M., Petasis N.A., Serhan C.N. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol 2003, 170:6266-6272.
8. Hachicha M., Pouliot M., Petasis N.A., Serhan C.N. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J Exp Med 1999, 189:1923-1930.
9. Leonard M.O., Hannan K., Burne M.J., Lappin D.W., Doran P., Coleman P., et al. 15-epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure. J Am Soc Nephrol 2002, 13:1657-1662.
10. Pouliot M., Serhan C.N. Lipoxin A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor-alpha-initiated neutrophil responses and trafficking: novel regulators of a cytokine-chemokine axis relevant to periodontal diseases. J Periodontal Res 1999, 34:370-373.
11. Jozsef L., Zouki C., Petasis N.A., Serhan C.N., Filep J.G. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci U S A 2002, 99:13266-13271.
12. Chiang N., Serhan C.N., Dahlen S.E., Drazen J.M., Hay D.W., Rovati G.E., et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006, 58:463-487.
13. Fiorucci S., Distrutti E., Mencarelli A., Morelli A., Laufor S.A., Cirino G., et al. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br J Pharmacol 2003, 139:1351-1359.
14. Gilroy D.W. The role of aspirin-triggered lipoxins in the mechanism of action of aspirin. Prostaglandins Leukot Essent Fatty Acids 2005, 73:203-210.
15. Mitchell S., Thomas G., Harvey K., Cottell D., Reville K., Berlasconi G., et al. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 2002, 13:2497-2507.
16. Fosbol E.L., Kober L., Torp-Pedersen C., Gislason G.H. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. Expert Opin Drug Saf 2010, 9:893-903.
17. Claria J., Serhan C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 1995, 92:9475-9479.
18. Ye Y., Lin Y., Atar S., Huang M.H., Perez-Polo J.R., Uretsky B.F., et al. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol Heart Circ Physiol 2006, 291:H1158-H1169.
19. Birnbaum Y., Ye Y., Rosanio S., Tavackoli S., Hu Z.Y., Schwarz E.R., et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 2005, 65:345-355.
20. Atar S., Ye Y., Lin Y., Freeberg S.Y., Nishi S.P., Rosanio S., et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 2006, 290:H1960-H1968.
21. Kim S.F., Huri D.A., Snyder S.H. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005, 310:1966-1970.
22. Ye Y., Keyes K.T., Zhang C., Perez-Polo J.R., Lin Y., Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010, 298:H1454-H1465.
23. Ye Y., Lin Y., Manickavasagam S., Perez-Polo J.R., Tieu B.C., Birnbaum Y. Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice. Am J Physiol Heart Circ Physiol 2008, 295:H2436-H2446.
24. Ye Y., Martinez J.D., Perez-Polo R.J., Lin Y., Uretsky B.F., Birnbaum Y. The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 2008, 295:H343-H351.
25. Birnbaum Y., Long B., Qian J., Perez-Polo J.R., Ye Y. Pioglitazone limits myocardial infarct size, activates akt, and upregulates cPLA2 and COX-2 in a PPAR-gamma-independent manner. Basic Res Cardiol 2011, 106:431-446.
26. Riera-Guardia N., Rothenbacher D. The effect of thiazolidinediones on adiponectin serum level: a meta-analysis. Diabetes Obes Metab 2008, 10:367-375.
27. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005, 11:1096-1103.
28. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
29. Ouchi N., Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007, 380:24-30.
30. Bajaj M., Suraamornkul S., Piper P., Hardies L.J., Glass L., Cersosimo E., et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004, 89:200-206.
31. Miyazaki Y., Mahankali A., Wajcberg E., Bajaj M., Mandarino L.J., DeFronzo R.A. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004, 89:4312-4319.
32. Ogasawara D., Shite J., Shinke T., Watanabe S., Otake H., Tanino Y., et al. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. Circ J 2009, 73:343-351.
33. Mizoguchi M., Tahara N., Tahara A., Nitta Y., Kodama N., Oba T., et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imag 2011, 4:1110-1118.
34. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., D'Agostino R.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. J Am Med Assoc 2006, 296:2572-2581.
35. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. J Am Med Assoc 2008, 299:1561-1573.
36. 4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A 2004, 101:15178-15183.
37. 4 formation: a randomized human trial. Arterioscler Thromb Vasc Biol 2006, 26:e14-17.